Enlivex Therapeutics Ltd. (ENLV)

NASDAQ: ENLV · IEX Real-Time Price · USD

1.322

-0.058 (-4.20%)

At close: Jul 2, 2024, 3:59 PM

1.320

-0.002 (-0.15%)

After-hours: Jul 2, 2024, 7:53 PM EDT

Enlivex Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Net Income	-29.07	-31.06	-14.47	-11.82	-9.38	Upgrade
Depreciation & Amortization	0.84	0.78	0.55	0.29	0.37	Upgrade
Share-Based Compensation	1.95	2.71	2.91	0.67	0.81	Upgrade
Other Operating Activities	2.76	3.62	-6.53	-0.14	1.16	Upgrade
Operating Cash Flow	-23.52	-23.95	-17.54	-11.01	-7.04	Upgrade
Capital Expenditures	-0.1	-8.12	-1.63	-1.02	-0.19	Upgrade
Acquisitions	0	0	0	0	1.54	Upgrade
Change in Investments	-25.87	70.65	-36.78	-19.96	-7.71	Upgrade
Investing Cash Flow	-25.97	62.52	-38.41	-20.98	-6.36	Upgrade
Share Issuance / Repurchase	0.36	0.15	60.98	33.08	8.31	Upgrade
Financing Cash Flow	0.36	0.15	60.98	33.08	8.31	Upgrade
Exchange Rate Effect	0	0	-0.41	0.39	0.83	Upgrade
Net Cash Flow	-49.13	38.72	5.03	1.1	-5.09	Upgrade
Free Cash Flow	-23.63	-32.08	-19.17	-12.03	-7.23	Upgrade
Free Cash Flow Per Share	-1.27	-1.74	-1.07	-0.91	-0.84	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).